Cochrane for Clinicians
Putting Evidence into Practice
Opioid Antagonists for the Treatment of Alcohol Dependence
Am Fam Physician. 2011 Nov 1;84(9):990-992.
A 45-year-old man comes to your office for evaluation after an arrest for driving under the influence of alcohol. He is concerned about his alcohol dependence, and is interested in medical help to quit drinking. You wonder if an opioid antagonist could help him abstain from alcohol.
Do opioid antagonists help patients with alcohol dependence to stop drinking?
Although it does not improve overall alcohol abstinence rates, the oral formulation of the opioid antagonist naltrexone (Revia) is moderately effective in decreasing the amount and frequency of alcohol consumption in patients with alcohol dependence.1 (Strength of Recommendation: C, based on consensus, disease-oriented evidence, usual practice, expert opinion, or case series.)
Background: Alcohol dependence belongs to the globally leading health risk factors. Therapeutic success of psychosocial programs for relapse prevention is moderate and could be increased by an adjuvant treatment with the opioid antagonists naltrexone and nalmefene (not available in the United States).
Objectives: To determine the effectiveness and tolerability of opioid antagonists in the treatment of alcohol dependence.
Search Strategy: We searched the Cochrane Drugs and Alcohol Group (CDAG) Specialized Register, PubMed, EMBASE, and CINAHL in January 2010, and asked manufacturers and researchers for unpublished trials.
Selection Criteria: All double-blind randomized controlled trials that compare the effects of naltrexone or nalmefene with placebo or active control on drinking-related outcomes.
Data Collection and Analysis: Two authors independently extracted outcome data. Trial quality was assessed by one author and cross-checked by a second author.
Main Results: Based on a total of 50 randomized controlled trials with 7,793 patients, naltrexone reduced the risk of heavy drinking to 83 percent of the risk in the placebo group (relative risk [RR] = 0.83; 95% confidence interval [CI], 0.76 to 0.90) and decreased drinking days by about 4 percent (mean difference [MD] = –3.89; 95% CI, –5.75 to –2.04). Significant effects were also demonstrated for the secondary outcomes of the review, including heavy drinking days (MD = –3.25; 95% CI, –5.51 to –0.99), consumed amount of alcohol (MD = –10.83; 95% CI, –19.69 to –1.97), and γ-glutamyltransferase levels (MD = –0.37; 95% CI, –18.99 to –1.75), whereas the effects on return to any drinking (RR = 0.96; 95% CI, 0.92 to 1.00) missed statistical significance. Adverse effects of naltrexone were mainly gastrointestinal problems (e.g., nausea; risk difference [RD] = 0.10; 95% CI, 0.07 to 0.13) and sedative effects (e.g., daytime sleepiness; RD = 0.09; 95% CI, 0.05 to 0.14). Based on a limited study sample, effects of injectable naltrexone and nalmefene missed statistical significance. Effects of industry-sponsored studies (RR = 0.90; 95% CI, 0.78 to 1.05) did not significantly differ from those of nonprofit-funded trials (RR = 0.84; 95% CI, 0.77 to 0.91), and the linear regression test did not indicate publication bias (P = .765).
Authors' Conclusions: Naltrexone appears to be an effective and safe strategy in alcoholism treatment. Even though the sizes of treatment effects might appear moderate in their magnitudes, these should be valued against the background of the relapsing nature of alcoholism and the limited therapeutic options currently available for its treatment.
These summaries have been derived from Cochrane reviews published in the Cochrane Database of Systematic Reviews in the Cochrane Library. Their content has, as far as possible, been checked with the authors of the original reviews, but the summaries should not be regarded as an official product of the Cochrane Collaboration; minor editing changes have been made to the text (http://www.cochrane.org).
Alcohol dependence is a disease with cognitive, behavioral, and physiologic symptoms in persons who continue to drink despite significant alcohol-related problems. Symptoms often include tolerance, withdrawal, and other physical and social impairments.2 Because opioid receptors likely play a role in mediating the pleasant effects of alcohol, the opioid antagonists naltrexone and nalmefene (not available in the United States) have been studied as potential treatments for alcohol dependence.3
This Cochrane review examined 50 randomized controlled trials to determine whether the use of opioid antagonists could help patients with alcohol dependence to stop drinking or drink less.1 The review included studies examining nalmefene and the oral and injectable (Vivitrol) formulations of naltrexone. Both agents in all formulations were compared with placebo; oral naltrexone also was compared with other medications, including acamprosate (Campral), aripiprazole (Abilify), nefazodone, and topiramate (Topamax). Combinations of oral naltrexone with acamprosate, ondansetron (Zofran), and sertraline (Zoloft) also were compared with placebo. Study participants were older than 18 years and had diagnosed alcohol abuse, alcohol dependence, or both. Most studies excluded persons with major psychiatric comorbidities and those who used illicit drugs. Most studies also provided concurrent psychosocial treatment to all participants. The primary end points were rates of return to heavy drinking, return to any drinking, and percentage of drinking days.
[corrected] Compared with placebo, oral naltrexone reduced the risk of return to heavy drinking by 17 percent (relative risk [RR] = 0.83; 95% confidence interval [CI], 0.76 to 0.90) and reduced the number of drinking days by 4 percent (mean difference [MD] = –3.89; 95% CI, –5.75 to –2.04). In addition, naltrexone reduced heavy drinking days by 3 percent (MD = –3.25; 95% CI, –5.51 to –0.99) and reduced alcohol consumption by 11 g (0.39 oz) on drinking days (MD = –10.83; 95% CI, –19.69 to –1.97). There was no statistically significant difference in return to any drinking (RR = 0.96; 95% CI, 0.92 to 1.00).
Adverse effects were more common with naltrexone than placebo. These included gastrointestinal effects (e.g., abdominal pain, decreased appetite, nausea, vomiting), as well as neurologic effects (e.g., drowsiness, fatigue, insomnia, weakness, somnolence, lethargy, blurred vision, decreased libido, dizziness, depression, nightmares, daytime sleepiness).
There are no established guidelines on the appropriate length of naltrexone treatment for alcohol dependence. One study recommends oral naltrexone for at least three months. If it is not successful in helping the patient remain abstinent, a longer course or higher dosage of oral naltrexone, or changing to the injectable form, may be considered.3
Physicians treating patients who use illicit intravenous drugs have been hopeful that using an injectable extended-release formulation of naltrexone would improve compliance. In a small subgroup analysis of injectable naltrexone, there was no statistically significant difference in the risk of return to any drinking (RR = 0.92; 95% CI, 0.84 to 1.00) or in the percentage of heavy drinking days (MD = –3.05; 95% CI, –8.46 to 2.35). There was a statistically significant 9 percent reduction in days of any drinking (MD = –8.54; 95% CI, –15.77 to –1.31).1
In another Cochrane review, the glutamate antagonist acamprosate was found to provide moderate benefit for maintaining abstinence from alcohol use in those who are dependent.4 In the Cochrane review on opioid antagonists, three clinical trials comparing naltrexone with acamprosate found no statistical difference in return to any drinking (RR = 0.97; 95% CI, 0.91 to 1.04), number of drinking days (MD = 3.06; 95% CI, –7.42 to 13.53), or risk of return to heavy drinking (RR = 0.96; 95% CI, 0.87 to 1.06).1 Adverse effect profiles differed. Naltrexone was associated with significantly more nausea (risk difference [RD] = 0.08; 95% CI, 0.03 to 0.13) and somnolence (RD = 0.07; 95% CI, 0.01 to 0.13), whereas acamprosate was associated with more diarrhea (RD = –0.27; 95% CI, –0.34 to –0.20). Individual trials analyzing naltrexone versus aripiprazole, nefazodone, and topiramate showed no medication to be statistically superior to naltrexone.
When the combination of naltrexone and acamprosate was compared with naltrexone alone, there was no statistical difference in return to heavy drinking (RR = 0.97; 95% CI, 0.75 to 1.26), any drinking (RR = 0.88; 95% CI, 0.61 to 1.28), or drinking days (MD = –1.10; 95% CI, –5.21 to 3.01). Combined treatment was associated with more diarrhea (RD = 0.37; 95% CI, 0.10 to 0.65) and more nausea (RD = 0.09; 95% CI, 0.14 to 0.26).
Three randomized trials compared nalmefene with placebo. No statistically significant difference was noted in return to heavy drinking, return to any drinking, reduction in drinking days, or amount of alcohol consumed. Nausea, dizziness, and insomnia were more common with nalmefene use.
Opioid antagonists modestly decrease alcohol consumption in patients with alcohol dependence, although they do not increase the likelihood that patients will stop drinking entirely. Given the lack of other more effective treatments for alcohol dependence, naltrexone is a useful adjunct to psychosocial treatment.
1. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000.
3. Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008;359(7):715–721.
4. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;(9):CD004332.
The Cochrane Abstract is a summary of a review from the Cochrane Library. It is accompanied by an interpretation that will help clinicians put evidence into practice. Drs. Yancey and Lumbad present a clinical scenario and question based on the Cochrane Abstract, followed by an evidence-based answer and a critique of the review. The practice recommendations in this activity are available at http://www.cochrane.org/reviews/en/ab001867.html.
The series coordinator for AFP is Kenny Lin, MD, Department of Family Medicine, Georgetown University School of Medicine, Washington, DC.
A collection of Cochrane for Clinicians published in AFP is available at http://www.aafp.org/afp/cochrane.
Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions